That's Sir Andrew Witty to you

All that talk about re-investing in Britain has paid off. GlaxoSmithKline ($GSK) CEO Andrew Witty (photo) was honored with a knighthood over New Year's after he promised increased spending on domestic facilities, staff and development. GSK's discounted pricing in poor countries must have helped, too. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.